Literature DB >> 7705430

Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures.

A W Wamil1, M Schmutz, C Portet, K F Feldmann, M J McLean.   

Abstract

The anticonvulsant compound oxcarbazepine and its principal 10-monohydroxy metabolite protected potently against electroshock-induced tonic hindlimb extension. Maximal plasma concentrations depended on dose and were reached < or = 1 h after an oral dose of oxcarbazepine and < 2 h after monohydroxy derivative. In mice, the ED50 was 14 mg/kg for oxcarbazepine and 20.5 mg/kg for the monohydroxy derivative, p.o. In rats, the ED50 was 13.5 mg/kg for oxcarbazepine and 17.0 mg/kg for monohydroxy derivative, p.o. This protective effect compared favorably with the efficacy of carbamazepine, phenytoin, phenobarbital and diazepam in the same test. As observed previously, valproate and ethosuximide were markedly less potent. The effect of oxcarbazepine and its monohydroxy derivative on sustained high frequency repetitive firing of sodium-dependent action potentials of mouse spinal cord neurons in cell culture was also examined using intracellular recording techniques. Both compounds reduced the percentage of neurons capable of sustained action potential firing in concentration-dependent manner. The EC50 for oxcarbazepine was 5 x 10(-8) M and that for monohydroxy derivative was 2 x 10(-8) M (P > 0.05 vs. oxcarbazepine). For comparison, the EC50 for carbamazepine was significantly higher (6 x 10(-7) M, P < 0.001 vs. oxcarbazepine and monohydroxy derivative). Limitation of firing by oxcarbazepine and the monohydroxy derivative depended on firing frequency and membrane potential and was enhanced by depolarization. Input resistance and resting membrane potential were not altered by either drug. The in vitro effect on action potential firing frequency occurred at concentrations below plasma levels of oxcarbazepine and monohydroxy derivative which protected animals against electroshock and were therapeutically effective in patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7705430     DOI: 10.1016/0014-2999(94)90787-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

Review 1.  Oxcarbazepine: an update of its efficacy in the management of epilepsy.

Authors:  K Wellington; K L Goa
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024.

Authors:  António F Ambrósio; Patrício Soares-Da-Silva; Caetana M Carvalho; Arsélio P Carvalho
Journal:  Neurochem Res       Date:  2002-02       Impact factor: 3.996

Review 3.  Newer agents for the treatment of painful diabetic peripheral neuropathy.

Authors:  Roy Freeman
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

4.  Severe overdosage with the antiepileptic drug oxcarbazepine.

Authors:  J M van Opstal; R Janknegt; J Cilissen; W H V M L'Ortije; J E Nel; F De Heer
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

5.  Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum.

Authors:  P C Waldmeier; P Martin; K Stöcklin; C Portet; M Schmutz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

6.  Spotlight on oxcarbazepine in epilepsy.

Authors:  Lynne M Bang; Karen L Goa
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Oxcarbazepine: a review of its use in children with epilepsy.

Authors:  Lynne Bang; Karen Goa
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

8.  CM101-mediated recovery of walking ability in adult mice paralyzed by spinal cord injury.

Authors:  A W Wamil; B D Wamil; C G Hellerqvist
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

9.  Overview of the clinical pharmacokinetics of oxcarbazepine.

Authors:  Gérard Flesch
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 10.  The neuropharmacology of the ketogenic diet.

Authors:  Adam L Hartman; Maciej Gasior; Eileen P G Vining; Michael A Rogawski
Journal:  Pediatr Neurol       Date:  2007-05       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.